Q32 Bio (QTTB) vs Upstream Bio (UPB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Q32 Bio (QTTB) has outperformed Upstream Bio (UPB) over the past year, gaining 170.6% versus a loss of 76.0%. Upstream Bio is the larger company by market cap ($249.2 million vs $240.8 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | QTTB | UPB |
|---|---|---|
| Share price | $8.09 | $4.55 |
| Market cap | $240.83M | $249.21M |
| 1-day change | +1.25% | -1.30% |
| YTD return | +143.67% | -83.24% |
| 1-year return | +170.57% | -75.95% |
| 5-year return | -92.75% | — |
| P/E ratio (TTM) | 2.57 | — |
| EPS (TTM) | $3.15 | $-2.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $23.57 | $33.68 |
| 52-week low | $1.91 | $4.37 |
| Distance from 52-week high | -65.68% | -86.49% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +389.49% | +584.40% |
| Average volume | 1.38M | 610.08K |
| Shares outstanding | 29.77M | 54.77M |
| Employees | 22 | 75 |
| Sector | Health Care | Healthcare |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- QTTB has outperformed UPB by 246.5 percentage points over the past year.
- The two companies sit in different sectors: Q32 Bio in Health Care and Upstream Bio in Healthcare.
About Q32 Bio
QTTB stock →Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
About Upstream Bio
UPB stock →Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.
Healthcare · Biotechnology · 75 employees
QTTB vs UPB FAQ
Which is bigger, Q32 Bio or Upstream Bio?
Upstream Bio (UPB) is larger, with a market capitalization of $249.21M compared with $240.83M for Q32 Bio (QTTB).
Which stock has performed better over the past year, QTTB or UPB?
QTTB returned +170.57% over the past 12 months, compared with -75.95% for UPB (price return, excluding dividends). Past performance does not predict future results.
Are Q32 Bio and Upstream Bio in the same industry?
No. Q32 Bio is in the Health Care sector, while Upstream Bio is in Healthcare.